 Shares of cancer diagnostics concern Veracyte, Inc. have shot up approximately 60 over the past month, snapping a deep decline. That said, valuations were stratospheric 22.6x FY21 sales at their peak, but shares of unprofitable Veracyte now trade at just under seven times FY22E sales net of cash. 